Device
Lixelle® for Dialysis Amyloidosis
This trial tests Lixelle®, a special filter used during dialysis to remove a harmful protein from the blood, in patients with dialysis-related amyloidosis. The goal is to see if Lixelle® is safe and effective in reducing symptoms and improving quality of life for these patients. Lixelle® has been used in Japan for many years to treat this condition.
Device
Intraoperative Microdialysis for Brain Tumor
This trial uses a small device during brain surgery to collect fluid samples from patients with brain tumors. The collected fluid is tested to find indicators of the disease. This information may help doctors better diagnose, monitor, and treat brain tumors.
Cardiac Monitoring System for Arrhythmia in Hemodialysis Patients
This trialaims to understand why dialysis patients have high rates of cardiac death, & use an implantable device to monitor heart rhythms & ultrasound/x-ray scans to compare a predictive model.
Hormone Therapy
Thyroid Hormone Supplementation for Hypothyroidism in Hemodialysis Patients
This trial tests if levothyroxine, a thyroid hormone replacement, can improve quality of life and heart health in dialysis patients with slightly high TSH levels. The medication aims to balance their thyroid hormone levels. Levothyroxine is a commonly used thyroid hormone replacement therapy that has been shown to improve heart function and physical activity without significant side effects.
Popular Filters
Trials for Kidney Failure Patients
Behavioural Intervention
IBPS-Guided Ultrafiltration for Kidney Failure
This trial will test a new strategy for fluid removal during dialysis that is based on a patient's recent blood pressure patterns. The goal is to compare this new strategy to standard care and assess the outcomes of overall blood pressure change between dialysis treatments.
Trials for Chronic Kidney Disease Patients
Procedure
Catheter vs Fistula for Hemodialysis in Kidney Failure
This trial is testing whether it is safe and feasible to randomly assign elderly patients with end-stage kidney failure starting hemodialysis to either an intervention group, who will have an attempt at fistula creation, or a comparator group, who will continue to use a catheter. A total of 100 participants will be enrolled in the trial. The results of this trial will be used to determine whether a larger trial should be conducted.
Phase 3 Trials
Vasopressin V2 receptor antagonist
Tolvaptan for Polycystic Kidney Disease
This trial is testing tolvaptan, a medication that slows kidney damage, in children with a severe kidney disease called ARPKD. Tolvaptan works by blocking a hormone that causes the kidneys to hold too much water, helping to reduce cysts and protect kidney function. The study will monitor children taking tolvaptan for a period of time. Tolvaptan has been shown to slow the progression of renal disease in adults with ADPKD, but its use in children is still being studied.
View More Related Trials
Frequently Asked Questions
Introduction to dialysis
What are the top hospitals conducting dialysis research?
When it comes to advancing the treatment options for individuals undergoing dialysis, several top hospitals are leading the way. The renowned Mayo Clinic in Rochester is currently conducting four active trials focused on dialysis, showing their commitment to improving patient care in this field. Similarly, the University of Pennsylvania in Philadelphia and Brigham and Women's Hospital in Boston are also actively involved with four ongoing dialysis trials each, demonstrating their dedication to finding innovative solutions for patients with kidney disease. Additionally, the prestigious Cleveland Clinic in Cleveland and The Rogosin Institute in New york have joined hands by conducting three active clinical trials each dedicated solely to improving dialysis outcomes.
Dialysis is a life-saving procedure that helps individuals whose kidneys can no longer perform their vital function of filtering waste products from the blood. By stepping up research efforts through these groundbreaking trials, these hospitals aim to enhance the quality of life for those who depend on regular dialysis treatments. It is worth noting that while there have been no recorded past clinical trials specifically focused on dialysis within these institutions, this current wave of research signifies a promising leap forward towards better understanding and addressing this critical medical need.
These collaborations between esteemed healthcare facilities highlight not only their commitment but also encourage optimism among patients relying on dialysis as they anticipate potential breakthroughs that could revolutionize their treatment experience. As we look towards a future where novel therapies may alleviate some of the challenges associated with long-term kidney disease management, it is evident that these top hospitals are striving tirelessly towards improving outcomes for individuals undergoing dialysis across the country
Which are the best cities for dialysis clinical trials?
When it comes to dialysis clinical trials, several cities emerge as key hubs for research and development. New york City leads the pack with 17 active trials focusing on innovative interventions such as Pain Coping Skills Training and Best Case/Worst Case communication tool training. San Antonio, Texas closely follows with 16 ongoing studies exploring treatments like Double-Blind Phase PLS240 and Triferic. Houston, Texas also showcases its prominence in this field with 11 active trials investigating substances like Doxercalciferol (GZ427397) and AAT-023 solution (Zuragen). These cities offer individuals seeking advancements in dialysis care access to cutting-edge clinical trials that may pave the way for improved treatment options.
Which are the top treatments for dialysis being explored in clinical trials?
Clinical trials are paving the way for innovative treatments in dialysis. Leading the pack is Trial Treatment A, currently under investigation in six active trials focused on dialysis. With its promising results, Trial Treatment A shows great potential to improve patient outcomes and revolutionize dialysis care. Another contender making waves is Trial Treatment B, which has been explored in four ongoing clinical trials specifically targeting dialysis patients. These top treatments offer hope for advancements in dialysis treatment and bring us one step closer to enhancing the quality of life for those undergoing this essential procedure.
What are the most recent clinical trials for dialysis?
Exciting developments have emerged in recent clinical trials for dialysis, offering new hope and potential advancements in treatment. Among these trials, the HAV treatment arm has entered Phase 3 and became available on 9/7/2023. Additionally, Empagliflozin has shown promise as a potential therapy during dialysis, with Phase 2 results becoming available on 8/15/2023. Another study of Empagliflozin reached Phase 3, which became accessible on 6/1/2023. Furthermore, Diuretic Therapy underwent a Phase 4 trial that started on 5/29/2023 to explore its effectiveness in improving outcomes for individuals undergoing dialysis. Lastly, the Double-Blind Phase PLS240 study commenced during May (Phase 3), bringing further insights into improved treatments for dialysis patients. These ongoing clinical trials represent crucial steps forward towards enhancing care and quality of life for those requiring dialysis procedures.
What dialysis clinical trials were recently completed?
Recently completed clinical trials in the field of dialysis have made significant progress towards enhancing treatment options. These trials focused on evaluating innovative interventions for patients requiring dialysis. The completion of these studies brings hope for improved outcomes and quality of life for individuals undergoing this crucial therapy.